Trial Profile
First in-human study of CXB 909 in volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2011
Price :
$35
*
At a glance
- Drugs CXB 909 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; Pharmacokinetics
- Sponsors CeNeRx BioPharma
- 10 Feb 2011 Results were reported in a CeNeRx media release.
- 10 Feb 2011 New trial record